| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Chief Scientific Officer
1 company
Lyssikatos Joseph P is a Chief Scientific Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 8 sells.
Estimated insider holdings value: $33.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $14.28 | $171,381.29 | -80.8% | +27.1% | +61.6% | |
| Dec 22, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 6,566 | $13.07 | $85,790.04 | -100% | +21.6% | +51.3% | |
| Dec 20, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 8,888 | $13.01 | $115,645.65 | -100% | +43.9% | +87.6% | |
| Nov 3, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 8,546 | $13.08 | $111,750.91 | -100% | +26.5% | +112.5% | |
| Sep 29, 2023 | ELVN Enliven Therapeutics, Inc. | Chief Scientific Officer | Sale+OE | 12,000 | $13.62 | $163,497.60 | -100% | +6.7% | +76.6% |